A quantitative multiplex nuclease protection assay reveals immunotoxicity gene expression profiles in the rabbit model for vaginal drug safety evaluation

Toxicology and Applied Pharmacology

Volumn 285, Issue 3, 2015, Pages 198-206

  Fichorova, Raina N ^a   Mendonca, Kevin ^a   Yamamoto, Hidemi S ^a   Murray, Ryan ^a   Chandra, Neelima ^b   Doncel, Gustavo F ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Anti HIV microbicides; BPI; EMP 1; Inflammation; RVI; Toll like receptors

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BIOLOGICAL MARKER; CD4 ANTIGEN; EPITHELIAL MEMBRANE PROTEIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 8; MESSENGER RNA; MICROBICIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; SECONDARY LYMPHOID TISSUE CHEMOKINE; SODIUM CHLORIDE; TENOFOVIR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG COMBINATION; NONOXINOL; OLIGOPEPTIDE; PHOSPHONIC ACID DERIVATIVE; TRANSCRIPTOME; VALYL-SERYL-TRYPTOPHYL-PHENYLALANYL-PHENYLALANYL-GLUTAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; GENE EXPRESSION; HISTOPATHOLOGY; HOST CELL; IMMUNOTOXICITY; LEUKOCYTE; NONHUMAN; NUCLEASE PROTECTION ASSAY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RABBIT MODEL; TISSUE INJURY; TISSUE SECTION; UPREGULATION; VAGINA DISEASE; VAGINAL IRRITATION; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; EVALUATION STUDY; FEMALE; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; METABOLISM; MUCOSA; PATHOLOGY; PROCEDURES; RABBIT; VAGINA;

ORYCTOLAGUS CUNICULUS;

ADENINE; ANIMALS; ANTI-HIV AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; EVALUATION STUDIES AS TOPIC; FEMALE; HOST-PATHOGEN INTERACTIONS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-8; MUCOUS MEMBRANE; NONOXYNOL; NUCLEASE PROTECTION ASSAYS; OLIGOPEPTIDES; ORGANOPHOSPHONATES; RABBITS; TOLL-LIKE RECEPTOR 4; TRANSCRIPTOME; VAGINA;

EID: 84928732020     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.02.017     Document Type: Article

References (50)

1. Abdool Karim Q., Abdool Karim S.S., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., Kharsany A.B., Sibeko S., Mlisana K.P., Omar Z., Gengiah T.N., Maarschalk S., Arulappan N., Mlotshwa M., Morris L., Taylor D., C.T.Group Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
2. Alt C., Harrison T., Dousman L., Fujita N., Shew K., Tran T.T., Shayesteh S., Matsukawa A., Mirsalis J., D'Andrea A. Increased CCL2 expression and macrophage/monocyte migration during microbicide-induced vaginal irritation. Curr. HIV Res. 2009, 7:639-649.
3. Banerjee A., Strazza M., Wigdahl B., Pirrone V., Meucci O., Nonnemacher M.R. Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis. J. Neurovirol. 2011, 17:291-302.
4. Banerjee A., Pirrone V., Wigdahl B., Nonnemacher M.R. Transcriptional regulation of the chemokine co-receptor CCR5 by the cAMP/PKA/CREB pathway. Biomed. Pharmacother. 2011, 65:293-297.
5. Bangsow T., Baumann E., Bangsow C., Jaeger M.H., Pelzer B., Gruhn P., Wolf S., von Melchner H., Stanimirovic D.B. The epithelial membrane protein 1 is a novel tight junction protein of the blood-brain barrier. J. Cereb. Blood Flow Metab. 2008, 28:1249-1260.
6. Canny G., Levy O. Bactericidal/permeability-increasing protein (BPI) and BPI homologs at mucosal sites. Trends Immunol. 2008, 29:541-547.
7. Canny G.O., Trifonova R.T., Kindelberger D.W., Colgan S.P., Fichorova R.N. Expression and function of bactericidal/permeability-increasing protein in human genital tract epithelial cells. J. Infect. Dis. 2006, 194:498-502.
8. Center for Drug Evaluation and Research Guidance for Industry. Guidance for Development of Vaginal Contraceptive Drugs. US Department of Health and Human Services, Food and Drug Administration Available at:, (Silver Spring, MD, USA). http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM131211.pdf.
9. Cost M., Dezzutti C.S., Clark M.R., Friend D.R., Akil A., Rohan L.C. Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model. Antimicrob. Agents Chemother. 2012, 56:3058-3066.
10. Costin G.E., Raabe H.A., Priston R., Evans E., Curren R.D. Vaginal irritation models: the current status of available alternative and in vitro tests. Altern. Lab. Anim. 2011, 39:317-337.
11. Eckstein P., Jackson M.C.N., Millman N., Sobrero A.J. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J. Reprod. Fertil. 1969, 20:85-93.
12. Fichorova R.N. Guiding the vaginal microbicide trials with biomarkers of inflammation. J. Acquir. Immune Defic. Syndr. 2004, 37(Suppl. 3):S184-S193.
13. Fichorova R.N. Safety Aspects of Topical Anti-HIV Microbicides. Drug Delivery and Development of Anti-HIV Microbicides 2015, 117-150. Pan Stanford Publishing Pte. Ltd., Singapore. J.D. Neves, B. Sarmento (Eds.).
14. Fichorova R.N., Tucker L.D., Anderson D.J. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J. Infect. Dis. 2001, 184:418-428.
15. Fichorova R.N., Cronin A.O., Lien E., Anderson D.J., Ingalls R.R. Response to Neisseria gonorrhoeae by cervicovaginal epithelial cells occurs in the absence of toll-like receptor 4-mediated signaling. J. Immunol. 2002, 168:2424-2432.
16. Fichorova R.N., Bajpai M., Chandra N., Hsiu J.G., Spangler M., Ratnam V., Doncel G.F. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol. Reprod. 2004, 71:761-769.
17. Fichorova R.N., Lai J.J., Schwartz J.L., Weiner D.H., Mauck C.K., Callahan M.M. Baseline variation and associations between subject characteristics and five cytokine biomarkers of vaginal safety among healthy non-pregnant women in microbicide trials. Cytokine 2011, 55:134-140.
18. Fichorova R.N., Lee Y., Yamamoto H.S., Takagi Y., Hayes G.R., Goodman R.P., Chepa-Lotrea X., Buck O.R., Murray R., Kula T., Beach D.H., Singh B.N., Nibert M.L. Endobiont viruses sensed by the human host - beyond conventional antiparasitic therapy. PLoS One 2012, 7:e48418.
19. Goff S.P. HIV: slipping under the radar. Nature 2013, 503:352-353.
20. Haaland R.E., Evans-Strickfaden T., Holder A., Pau C.P., McNicholl J.M., Chaikummao S., Chonwattana W., Hart C.E. UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application. Antimicrob. Agents Chemother. 2012, 56:3592-3596.
21. Hillier S.L., Moench T., Shattock R., Black R., Reichelderfer P., Veronese F. In vitro and in vivo: the story of nonoxynol 9. J. Acquir. Immune Defic. Syndr. 2005, 39:1-8.
22. Kiser P.F., Mahalingam A., Fabian J., Smith E., Damian F.R., Peters J.J., Katz D.F., Elgendy H., Clark M.R., Friend D.R. Design of tenofovir-UC781 combination microbicide vaginal gels. J. Pharm. Sci. 2012, 101:1852-1864.
23. Kopp E., Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr. Opin. Immunol. 2003, 15:396-401.
24. Leviton A., O'Shea T.M., Bednarek F.J., Allred E.N., Fichorova R.N., Dammann O., Investigators E.S. Systemic responses of preterm newborns with presumed or documented bacteraemia. Acta Paediatr. 2012, 101:355-359.
25. Lozenski K., Kish-Catalone T., Pirrone V., Rando R.F., Labib M., Wigdahl B., Krebs F.C. Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model. J. Biomed. Biotechnol. 2011, 2011:941061.
26. Lozenski K., Ownbey R., Wigdahl B., Kish-Catalone T., Krebs F.C. Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety. BMC Pharmacol. Toxicol. 2012, 13:9.
27. Ma Z., Lu F.X., Torten M., Miller C.J. The number and distribution of immune cells in the cervicovaginal mucosa remain constant throughout the menstrual cycle of rhesus macaques. Clin. Immunol. 2001, 100:240-249.
28. Martel R.R., Botros I.W., Rounseville M.P., Hinton J.P., Staples R.R., Morales D.A., Farmer J.B., Seligmann B.E. Multiplexed screening assay for mRNA combining nuclease protection with luminescent array detection. Assay Drug Dev. Technol. 2002, 1:61-71.
29. Mauck C.K., Lai J.J., Weiner D.H., Chandra N., Fichorova R.N., Dezzutti C.S., Hillier S.L., Archer D.F., Creinin M.D., Schwartz J.L., Callahan M.M., Doncel G.F. Toward early safety alert endpoints: exploring biomarkers suggestive of microbicide failure. AIDS Res. Hum. Retrovir. 2013, 29:1475-1486.
30. Mesquita P.M.M., Cheshenko N., Wilson S.S., Mhatre M., Guzman E., Fakioglu E., Keller M.J., Herold B.C. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J. Infect. Dis. 2009, 200:599-608.
31. Obiero J., Mwethera P.G., Wiysonge C.S. Topical microbicides for prevention of sexually transmitted infections. Cochrane Database Syst. Rev. 2012, 6:CD007961.
32. Pirrone V., Thakkar N., Jacobson J.M., Wigdahl B., Krebs F.C. Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob. Agents Chemother. 2011, 55:1831-1842.
33. Poonia B., Wang X., Veazey R.S. Distribution of simian immunodeficiency virus target cells in vaginal tissues of normal rhesus macaques: implications for virus transmission. J. Reprod. Immunol. 2006, 72:74-84.
34. Pulaganti M., Banaganapalli B., Mulakayala C., Chitta S.K., M.A.C. Molecular modeling and docking studies of O-succinylbenzoate synthase of M. tuberculosis-a potential target for antituberculosis drug design. Appl. Biochem. Biotechnol. 2014, 172:1407-1432.
35. Roberts R.A., Sabalos C.M., LeBlanc M.L., Martel R.R., Frutiger Y.M., Unger J.M., Botros I.W., Rounseville M.P., Seligmann B.E., Miller T.P., Grogan T.M., Rimsza L.M. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Lab. Investig. 2007, 87:979-997.
36. Rustagi A., Gale M. Innate antiviral immune signaling, viral evasion and modulation by HIV-1. J. Mol. Biol. 2014, 426:1161-1177.
37. Sawada H., Taniguchi K., Takami K. Improved toxicogenomic screening for drug-induced phospholipidosis using a multiplexed quantitative gene expression ArrayPlate assay. Toxicol. in Vitro 2006, 20:1506-1513.
38. Schultz H., Weiss J.P. The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease. Clin. Chim. Acta 2007, 384:12-23.
39. Strazza M., Pirrone V., Wigdahl B., Nonnemacher M.R. Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res. 2011, 1399:96-115.
40. Taylor V., Welcher A.A., Program A.E., Suter U. Epithelial membrane protein-1, peripheral myelin protein 22, and lens membrane protein 20 define a novel gene family. J. Biol. Chem. 1995, 270:28824-28833.
41. Trifonova R.T., Pasicznyk J.M., Fichorova R.N. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo. Antimicrob. Agents Chemother. 2006, 50:4005-4010.
42. Trifonova R.T., Bajpai M., Pasicznyk J.M., Chandra N., Doncel G.F., Fichorova R.N. Biomarkers of leukocyte traffic and activation in the vaginal mucosa. Biomarkers 2007, 12:608-622.
43. Trifonova R.T., Doncel G.F., Fichorova R.N. Polyanionic microbicides modify Toll-like receptor-mediated cervicovaginal immune responses. Antimicrob. Agents Chemother. 2009, 53:1490-1500.
44. Van Damme L., Niruthisard S., Atisook B.K., Boer K., Dally L., Laga M., Lange J.M., Karam M., Perriens J.H. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS 1998, 12:433-437.
45. Van Damme L., Chandeying V., Ramjee G., Rees H., Sirivonrangson P., Laga M., Perriens J. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 Phase II Study Group. AIDS 2000, 14:85-88.
46. Van Damme L., Ramjee G., Alary M., Vuylsteke B., Chandeying V., Rees H., Sirivongrangson P., Mukenge-Tshibaka L., Ettiegne-Traore V., Uaheowitchai C., Karim S., Masse B., Perriens J., Laga M., C.-S.Group Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002, 360:971-977.
47. Vercammen E., Staal J., Beyaert R. Sensing of viral infection and activation of innate immunity by toll-like receptor 3. Clin. Microbiol. Rev. 2008, 21:13-25.
48. Weiss J., Elsbach P., Olsson I., Odeberg H. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J. Biol. Chem. 1978, 253:2664-2672.
49. Xu H., Wang X., Veazey R.S. Mucosal immunology of HIV infection. Immunol. Rev. 2013, 254:10-33.
50. Zhong M., He B., Yang J., Bao R., Zhang Y., Zhou D., Chen Y., Li L., Han C., Yang Y., Sun Y., Cao Y., Li Y., Shi W., Jiang S., Zhang X., Yan H. L-selectin and P-selectin are novel biomarkers of cervicovaginal inflammation for preclinical mucosal safety assessment of anti-HIV-1 microbicide. Antimicrob. Agents Chemother. 2012, 56:3121-3132.